Efficacy and safety of tofacitinib in young patients aged 2 to less than 18 years with polyarticular course Juvenile Idiopathic Arthritis (JIA)
Efficacy, Safety, and Tolerability of Tofacitinib for Treatment of Polyarticular Course Juvenile Idiopathic Arthritis (JIA) in Children and Adolescent Subjects
Category & Conditions: Immune System Diseases and Conditions
Medicine: XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT): NCT02592434
Protocol ID: A3921104
PrintDownloadOpen Plain Language Summary Result: Click here